Physician profile
Kabeer Burman
NPI 1003137399
$1,673.31
in general payments reported to CMS, 2019-2025
23 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $82.81 · 2021: $109 · 2022: $97.40 · 2023: $207 · 2024: $496 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $243.82 | 2021-2025 | Teflaro, Dalvance, Avycaz |
| Tris Pharma INC | $185.02 | 2024-2025 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.48 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $137.53 | 2019-2023 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $135.30 | 2019-2024 | |
| Axsome Therapeutics, INC. | $112.62 | 2025 | Auvelity |
| Novo Nordisk INC | $97.59 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.82 | 2024-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $92.02 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $79.28 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $63.29 | 2020-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $39.84 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Inari Medical, INC. | $37.05 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phathom Pharmaceuticals, INC. | $31.69 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $31.01 | 2019-2024 | Boostrix, Shingrix, Arexvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.43 | 2025 | |
| Portola Pharmaceuticals, LLC | $23.07 | 2020 | |
| Medtronic, INC. | $18.51 | 2024 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $18.25 | 2024 | Heplisav-B |
| Ibsa Pharma INC. | $17.68 | 2024 | Licart, Tirosint |
| Astellas Pharma US INC | $17.55 | 2025 | Veozah |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.31 | 2021 | |
| Stryker Corporation | $15.15 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kabeer Burman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.